EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022
October 26, 2022 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 17, 2022 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy
September 29, 2022 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 16, 2022 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
September 06, 2022 16:01 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments
August 03, 2022 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
August 02, 2022 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
July 27, 2022 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Financial Update
July 18, 2022 07:30 ET
|
EyePoint Pharmaceuticals, Inc.
- Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD announced at ASRS 2022 Annual Meeting - Phase 2 clinical trial (DAVIO...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 18, 2022 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...